Open Menu
About
back
About
News
Event Calendar
Contacts
Tech Licensing
back
Tech Licensing
Innovators
back
Innovators
Report a New Innovation
Disclose Biological Materials
Innovators’ Guide
FAQ & Resources
Market Your Tech
Startups
Industry
Fellows Program
Ventures
The Hub
back
The Hub
Advisors
Apply
Client Resources
Companies
The Collaboratory for Women Innovators
back
The Collaboratory for Women Innovators
Programs
Contact
Donate
Sid Martin Bio
back
Sid Martin Bio
Why Us
Companies
Client Resources
Community
Apply
UF Research
About
News
Event Calendar
Contacts
Tech Licensing
Innovators
Report a New Innovation
Disclose Biological Materials
Innovators’ Guide
FAQ & Resources
Market Your Tech
Startups
Industry
Fellows Program
Ventures
The Hub
Advisors
Apply
Client Resources
Companies
The Collaboratory for Women Innovators
Programs
Contact
Donate
Sid Martin Bio
Why Us
Companies
Client Resources
Community
Apply
UF Research
← Back to All Technologies
Category:
Technology Classifications > Human Health Care > Therapeutics
Bookmark this page
Download as PDF
For more information, complete the form below. We'll respond via email.
Inventors:
Daiqing Liao
William Roush
Ryan Stowe
Benzoylhydrazide HDAC Inhibitors with Low Toxicity for Treating Cancer
Case ID:
MP14839_1
Web Published:
5/14/2019
Compounds Display Potent Inhibition of Cancer-Causing Enzymes and Suppression of Solid Tumor Growth
This class of small-molecule HDAC inhibitors has a novel benzoylhydrazide scaffold with potential to treat cancer, neurodegenerative disorders, and metabolic diseases. Cancer is the second leading cause of death in the United States, with more than 1.5 million people diagnosed every year. There are four HDAC inhibitors approved for cancer therapy, but those are only approved for treating hematologic malignancies such as T-cell lymphomas and multiple myelomas. Additionally, HDAC inhibitors undergoing clinical trials are continuing to face issues with dose-limiting toxicity and efficacy against solid tumors and other human diseases. Therefore, the market is in need of an HDAC inhibitor with broad therapeutic applications and low toxicity that can meet the stringent criteria for FDA approval. Researchers at the University of Florida in collaboration with scientists at the Scripps Research Institute have conducted a high-throughput screening and identified a group of benzoylhydrazide HDAC inhibitors that induces histone hyperacetylation and suppresses cancer cell proliferation. Medicinal chemistry efforts have led to optimized analogs with low nanomolar HDAC inhibition potency. Initial
in vivo
animal experiments show that these compounds are not toxic and exhibit good pharmacokinetic properties. These compounds are under active preclinical development for cancer therapy.
Application
HDAC inhibitor for treating cancer and other diseases (neurologic, cardiovascular, and metabolic disorders)
Advantages
Demonstrates potential for broad therapeutic applications, offering treatment for various forms of cancer and other diseases
Exhibits class I HDAC isoform-specificity and low toxicity, outperforming current HDAC inhibitors in clinical trials
Technology
University of Florida researchers have discovered a group of benzoylhydrazide compounds through a high-throughput screen and medicinal chemistry efforts that could potentially treat cancer, neurodegenerative disorders, and metabolic diseases. The compounds display potent
in vitro
inhibition of class I HDACs and inhibited cancer growth
in vitro
. The compounds? inhibitory activity was confirmed in cell-based assays and suppressed cancer cell proliferation of diverse cancer cell lines.
In vivo
animal experiments indicate that these compounds are safe and exhibit good pharmaceutical properties. The benzoylhydrazide HDAC inhibitor is currently under active preclinical development for cancer therapy.
Patent Information:
App Type:
Patent No.:
Patent Status:
ORD/UTIL
10,807,944
Issued
Direct Link:
https://ufinnovate.technologypublisher.com/tech/Benzoylhydrazide_HDAC_Inhibitors_with_Low_Toxicity_for_Treating_Cancer
Case ID:
MP14839_1